StockWatch
·

Suven Pharmaceuticals Ltd Q4 FY25 Results

COHANCEQ4 FY25 Results
Filing
MetricValue ( Cr)vs Q3 FY25
Revenue402.0230.9%
Total Income412.5927.8%
Expenditure360.9969.4%
PBT51.6053.0%
Net Profit38.7353.5%
OPM18.30%4.60pp
NPM9.39%16.41pp
EPS1.6549.4%
View full financials

Informational and educational content only. Not investment advice.